NO20062594L - Transdermal delivery system of hormones without penetration enhancers - Google Patents

Transdermal delivery system of hormones without penetration enhancers

Info

Publication number
NO20062594L
NO20062594L NO20062594A NO20062594A NO20062594L NO 20062594 L NO20062594 L NO 20062594L NO 20062594 A NO20062594 A NO 20062594A NO 20062594 A NO20062594 A NO 20062594A NO 20062594 L NO20062594 L NO 20062594L
Authority
NO
Norway
Prior art keywords
hormones
patch
penetration enhancers
delivery system
transdermal delivery
Prior art date
Application number
NO20062594A
Other languages
English (en)
Other versions
NO341989B1 (no
Inventor
Michael Dittgen
Thomas Langguth
Dirk Schenk
Stefan Bracht
Petra Huber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062594(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20062594L publication Critical patent/NO20062594L/no
Publication of NO341989B1 publication Critical patent/NO341989B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen angår et plaster som omfatter et legemiddelinneholdende lag med lavt innhold av hormon, slik som gestoden, og eventuelt et østrogen (f.eks. etiny-lestradiol). Ved administrasjon av plasteret til en kvinne, oppnås plasmanivåer på minst 1,0 ng/ml av gestoden ved steady-state-betingelser uten behov for inkorporering av penetrasjonsenhancere eller permeasjonsenhancere i det legemiddelinneholdende laget. Tilfredsstillende plasmanivaer i hormonene oppnås også gjennom en periode på minst 1 uke, idet plasteret gjøres anvendelig til bruk ved svangerskapsforebygging hos kvinner med et prinsipp om administrasjon av plastrene én gang ukentlig.
NO20062594A 2003-12-12 2006-06-06 Transdermal administrasjon av hormoner uten behov for penetrasjonsenhancere. NO341989B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12
PCT/IB2004/052752 WO2005058287A2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers

Publications (2)

Publication Number Publication Date
NO20062594L true NO20062594L (no) 2006-07-10
NO341989B1 NO341989B1 (no) 2018-03-12

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062594A NO341989B1 (no) 2003-12-12 2006-06-06 Transdermal administrasjon av hormoner uten behov for penetrasjonsenhancere.

Country Status (15)

Country Link
JP (1) JP4965263B2 (no)
KR (1) KR101168449B1 (no)
CN (1) CN1913878B (no)
AU (1) AU2004298930B2 (no)
BR (1) BRPI0417530B8 (no)
CA (1) CA2549916C (no)
CU (1) CU23868B1 (no)
EA (1) EA011160B1 (no)
EC (1) ECSP066694A (no)
IL (1) IL176112A (no)
MX (1) MXPA06006682A (no)
NO (1) NO341989B1 (no)
NZ (1) NZ548091A (no)
WO (1) WO2005058287A2 (no)
ZA (1) ZA200605713B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541807A (en) 2003-02-21 2009-07-31 Bayer Schering Pharma Ag UV stable transdermal therapeutic plaster
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
FR2900048B1 (fr) * 2006-04-21 2012-11-16 Oreal Compositions comprenant un derive diphenyl-methane hydroxyle
WO2012031999A2 (en) 2010-09-06 2012-03-15 Bayer Pharma Aktiengesellschaft Low-dose transdermal patches with high drug release
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
AU2013212005A1 (en) * 2012-01-27 2014-07-31 Agile Therapeutics, Inc. Transdermal hormone delivery
AU2016264137B2 (en) * 2015-05-18 2021-08-19 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004397A1 (de) * 1988-10-27 1990-05-03 Schering Aktiengesellschaft Berlin Und Bergkamen Mittel zur transdermalen applikation enthaltend gestoden
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
EP0555360A1 (en) * 1990-10-29 1993-08-18 Alza Corporation Transdermal contraceptive formulations, methods and devices
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
WO1996015776A1 (en) * 1994-11-18 1996-05-30 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP4167750B2 (ja) * 1997-04-16 2008-10-22 久光製薬株式会社 経皮吸収用基剤及び該基剤を含有する経皮吸収製剤
JP4399044B2 (ja) * 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
EP1197212A4 (en) * 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Also Published As

Publication number Publication date
MXPA06006682A (es) 2006-08-11
KR20060128910A (ko) 2006-12-14
BRPI0417530A (pt) 2007-03-13
AU2004298930A1 (en) 2005-06-30
BRPI0417530B1 (pt) 2018-01-23
IL176112A (en) 2011-02-28
WO2005058287A3 (en) 2006-03-02
EA200601089A1 (ru) 2006-12-29
CN1913878A (zh) 2007-02-14
CU20100143A7 (es) 2011-10-31
JP2007513938A (ja) 2007-05-31
BRPI0417530B8 (pt) 2021-05-25
WO2005058287A2 (en) 2005-06-30
IL176112A0 (en) 2006-10-05
NO341989B1 (no) 2018-03-12
NZ548091A (en) 2009-12-24
ZA200605713B (en) 2008-01-08
ECSP066694A (es) 2006-10-31
JP4965263B2 (ja) 2012-07-04
EA011160B1 (ru) 2009-02-27
KR101168449B1 (ko) 2012-07-25
CU23868B1 (es) 2013-03-27
CA2549916C (en) 2013-09-17
AU2004298930B2 (en) 2009-11-26
CN1913878B (zh) 2010-05-26
CA2549916A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
CY1115064T1 (el) Διαδερμικο συστημα παραδοσης ορμονων χωρις ενισχυτες διεισδυσης
DK0836506T4 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
NO962933L (no) Östradiol-penetrasjonsforsterker for transdermal administrering
DK0921774T3 (da) Transdermal medikamentleveringsmatrice til administration af östradiol og et andet steroid
HUP9902952A1 (hu) Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása
NO20030961L (no) Farmasöytiske preparater samt metode for behandling av hypogonadisme
NO980277L (no) Hormonplaster
CU20100143A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
NO953874L (no) Farmasöytisk preparat inneholdende lipofile legemidler
CY1105716T1 (el) Διαδερμικο εμπλαστρο σταθερο εναντι uv
NO20084088L (no) Preparater og fremgangsmater for levering av aminofunksjonelle legemidler
JP2008517934A5 (no)
ATE322272T1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetin
ATE382356T1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
AU1393701A (en) Transdermal therapeutic system containing highly volatile active ingredients
CA2403949A1 (en) Transdermal therapeutic system for the delivery of lerisetron
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
NO990498L (no) 19-nor-cholansteroider som neurokjemiske initiatorer av forandring i human, hypotalamisk funksjon
DK0825865T3 (da) Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat
WO2005046600A3 (en) Transdermal tulobuterol delivery
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
AR003413A1 (es) Parches medicinales para la administracion transdermica de risperidona con liberacion controlada a traves de la piel intacta durante un periodo de tiempo prolongado
DE50208253D1 (de) Transdermales therapeutisches system zur verabreichung des partiellen dopamin-d2-agonisten aripiprazol

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

MM1K Lapsed by not paying the annual fees